China Pharma Holdings (CPHI) Capital Expenditures (2010 - 2025)
China Pharma Holdings' (CPHI) quarterly Capital Expenditures came in at $454.0 in Q4 2025, down 97.68% YoY from $19545.0 in Q4 2024, and down 25.7% on a QoQ basis from $611.0 in Q3 2025.
China Pharma Holdings (CPHI) Capital Expenditures (2010 - 2025) Analysis & Trends
China Pharma Holdings (CPHI) has 16 years of Capital Expenditures data on file, last reported at $454.0 in Q4 2025.
- Quarterly Capital Expenditures fell 97.68% year-over-year to $454.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $59324.0 (down 27.92% YoY) and the FY2025 annual result came in at $59324.0, up 54.45% from the prior year.
- Capital Expenditures eased to $454.0 in Q4 2025, from $611.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $415977.0 in Q3 2021 to a low of -$55964.0 in Q1 2023.
- A 5-year average of $56635.2 and a median of $2959.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures plunged 4123.29% — and 2024, when it soared 331.74%.
- Tracing CPHI's Capital Expenditures over 5 years: stood at $7056.0 in 2021, then tumbled by 486.45% to -$27268.0 in 2022, then soared by 116.6% to $4527.0 in 2023, then jumped by 331.74% to $19545.0 in 2024, then slumped by 97.68% to $454.0 in 2025.
- The last three Capital Expenditures figures came in at $454.0 (Q4 2025), $611.0 (Q3 2025), and -$65.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 42.35 Mn | 42.04 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 454.00 |
| Dec 31, 2025 | 454.00 |
| Sep 30, 2025 | 611.00 |
| Sep 30, 2025 | 611.00 |
| Jun 30, 2025 | -65.00 |
| Jun 30, 2025 | -65.00 |
| Mar 31, 2025 | 58,324.00 |
| Mar 31, 2025 | 58,324.00 |
| Dec 31, 2024 | 19,545.00 |
| Dec 31, 2024 | 19,545.00 |
| Sep 30, 2024 | -9,220.00 |
| Sep 30, 2024 | -9,220.00 |
| Dec 31, 2023 | 4,527.00 |
| Dec 31, 2023 | 4,527.00 |
| Sep 30, 2023 | 67,455.00 |
| Sep 30, 2023 | 67,455.00 |
| Jun 30, 2023 | -4,501.00 |
| Jun 30, 2023 | -4,501.00 |
| Mar 31, 2023 | -55,964.00 |
| Mar 31, 2023 | -55,964.00 |